References
Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37(12):1015–27.
Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663–73.
Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37(8):658–67.
Kemp Bohan PM, Kirby DT, Chick RC, et al. Adjuvant chemotherapy in resectable gallbladder cancer is underutilized despite benefits in node-positive patients. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08973-x.
Kemp Bohan PM, O'Shea AE, Ellis OV, et al. Rates, predictors, and outcomes of portal lymphadenectomy in patients with resectable, non-metastatic gallbladder cancer. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-09667-8.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
The authors declare no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kemp Bohan, P.M., Nelson, D.W. & Vreeland, T.J. ASO Author Reflections: Contemporary Analysis of Impact of Lymphadenectomy on Survival in Nonmetastatic Gallbladder Cancer. Ann Surg Oncol 28, 2973–2974 (2021). https://doi.org/10.1245/s10434-021-09668-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-021-09668-7